JP2015506356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506356A5 JP2015506356A5 JP2014550424A JP2014550424A JP2015506356A5 JP 2015506356 A5 JP2015506356 A5 JP 2015506356A5 JP 2014550424 A JP2014550424 A JP 2014550424A JP 2014550424 A JP2014550424 A JP 2014550424A JP 2015506356 A5 JP2015506356 A5 JP 2015506356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- weight
- total
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 13
- 239000008199 coating composition Substances 0.000 claims 8
- 201000004681 Psoriasis Diseases 0.000 claims 6
- 206010003246 arthritis Diseases 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- 201000000306 sarcoidosis Diseases 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical group CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 239000003086 colorant Substances 0.000 claims 3
- 229960005168 croscarmellose Drugs 0.000 claims 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011674 Cutaneous sarcoidosis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000003646 skin sarcoidosis Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- -1 glidants Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161580626P | 2011-12-27 | 2011-12-27 | |
| US61/580,626 | 2011-12-27 | ||
| PCT/US2012/071623 WO2013101810A1 (en) | 2011-12-27 | 2012-12-26 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506356A JP2015506356A (ja) | 2015-03-02 |
| JP2015506356A5 true JP2015506356A5 (https=) | 2016-02-18 |
| JP6161629B2 JP6161629B2 (ja) | 2017-07-12 |
Family
ID=47459206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550424A Active JP6161629B2 (ja) | 2011-12-27 | 2012-12-26 | （＋）−２−［１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−４−アセチルアミノイソインドリン−１，３−ジオンの製剤 |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20130164376A1 (https=) |
| EP (3) | EP3756650B1 (https=) |
| JP (1) | JP6161629B2 (https=) |
| KR (3) | KR20210033073A (https=) |
| CN (1) | CN104136003A (https=) |
| AU (1) | AU2012362562B2 (https=) |
| BR (1) | BR112014015923B1 (https=) |
| CA (1) | CA2861594A1 (https=) |
| CL (1) | CL2014001726A1 (https=) |
| CO (1) | CO7000777A2 (https=) |
| CR (1) | CR20140314A (https=) |
| CY (1) | CY1123174T1 (https=) |
| DK (2) | DK2797581T3 (https=) |
| EA (1) | EA027801B1 (https=) |
| EC (1) | ECSP14007965A (https=) |
| ES (2) | ES2799448T3 (https=) |
| FI (1) | FI3756650T3 (https=) |
| HR (2) | HRP20251291T1 (https=) |
| HU (2) | HUE050327T2 (https=) |
| IL (1) | IL233296B (https=) |
| LT (2) | LT3756650T (https=) |
| MX (2) | MX373934B (https=) |
| NI (1) | NI201400068A (https=) |
| PE (1) | PE20142318A1 (https=) |
| PH (1) | PH12014501495B1 (https=) |
| PL (2) | PL2797581T3 (https=) |
| PT (2) | PT3756650T (https=) |
| RS (2) | RS60415B1 (https=) |
| SG (2) | SG10201605251VA (https=) |
| SI (2) | SI3756650T1 (https=) |
| SM (2) | SMT202000339T1 (https=) |
| UA (1) | UA113750C2 (https=) |
| WO (1) | WO2013101810A1 (https=) |
| ZA (1) | ZA201404629B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013040120A1 (en) | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
| RS60415B1 (sr) | 2011-12-27 | 2020-07-31 | Amgen (Europe) GmbH | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona |
| EP3143004B1 (en) | 2014-05-11 | 2020-09-02 | Mapi Pharma Limited | Amorphous form of apremilast |
| WO2016016824A1 (en) | 2014-07-29 | 2016-02-04 | Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
| CA2987912C (en) * | 2015-06-30 | 2023-01-24 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| CZ20165A3 (cs) * | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | Způsoby přípravy amorfního apremilastu |
| BR112018076114A2 (pt) | 2016-06-15 | 2019-03-26 | Torrent Pharmaceuticals Limited | composições tópicas de apremilast |
| WO2020222773A1 (en) * | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| ES2823927B2 (es) * | 2019-11-07 | 2022-01-18 | Beijing Enbiwo Biological Tech Co Ltd | Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales |
| KR20220047105A (ko) | 2020-10-08 | 2022-04-15 | 주식회사 엔비피헬스케어 | 아프레밀라스트를 함유하는 약학 조성물 |
| CN112245403B (zh) * | 2020-10-23 | 2022-04-22 | 杭州朱养心药业有限公司 | 磷酸二酯酶-4抑制剂及其口服固体组合物 |
| EP4183389A1 (en) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apremilast |
| WO2023118043A1 (en) | 2021-12-22 | 2023-06-29 | Biohorm, S.L. | Pharmaceutical compositions of apremilast |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| EP0716597A1 (en) | 1993-08-30 | 1996-06-19 | Warner-Lambert Company | Tablet coating based on a melt-spun mixture of a saccharide and apolymer |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| NZ333903A (en) | 1996-07-24 | 2000-02-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| CA2389293A1 (en) * | 1999-10-29 | 2001-05-10 | Smithkline Beecham Corporation | Method for administering a phosphodiesterase 4 inhibitor |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| CN1511420A (zh) | 2001-11-09 | 2004-07-07 | ���µ�����ҵ��ʽ���� | 运动图像编码方法和装置 |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20120039065A (ko) | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| BRPI0509019A (pt) | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US20050239842A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| JP2008520731A (ja) | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物 |
| BRPI0518793A2 (pt) | 2004-12-01 | 2008-12-09 | Celgene Corp | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica |
| EP1855656A2 (en) * | 2005-02-15 | 2007-11-21 | Wyeth | Orally bioavailable cci-779 tablet formulations |
| WO2006097344A1 (en) * | 2005-03-17 | 2006-09-21 | Synthon B.V. | Pharmaceutical tablets of crystalline type ii aripiprazole |
| WO2006111980A2 (en) | 2005-04-20 | 2006-10-26 | Ideal Cures Pvt. Ltd. | Pva based film coating and film coating compositions |
| SI1928492T1 (sl) | 2005-09-01 | 2011-09-30 | Celgene Corp | Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo |
| US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
| US8927546B2 (en) * | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| CA2718601A1 (en) * | 2008-03-27 | 2009-10-01 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| DE102008047910A1 (de) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| EP2196465A1 (en) * | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| PE20120580A1 (es) | 2009-02-10 | 2012-05-23 | Celgene Corp | Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis |
| JP5784623B2 (ja) * | 2009-11-13 | 2015-09-24 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | 速放性錠剤製剤 |
| MX2012004741A (es) | 2009-11-19 | 2012-05-22 | Celgene Corp | Apremilast para el tratamiento de sarcoidosis. |
| WO2012083017A2 (en) * | 2010-12-16 | 2012-06-21 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
| RS60415B1 (sr) | 2011-12-27 | 2020-07-31 | Amgen (Europe) GmbH | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona |
-
2012
- 2012-12-26 RS RS20200715A patent/RS60415B1/sr unknown
- 2012-12-26 DK DK12808662.6T patent/DK2797581T3/da active
- 2012-12-26 SI SI201232098T patent/SI3756650T1/sl unknown
- 2012-12-26 JP JP2014550424A patent/JP6161629B2/ja active Active
- 2012-12-26 PT PT201726155T patent/PT3756650T/pt unknown
- 2012-12-26 KR KR1020217008170A patent/KR20210033073A/ko not_active Ceased
- 2012-12-26 US US13/727,366 patent/US20130164376A1/en not_active Abandoned
- 2012-12-26 KR KR1020147020953A patent/KR102035362B1/ko active Active
- 2012-12-26 SG SG10201605251VA patent/SG10201605251VA/en unknown
- 2012-12-26 WO PCT/US2012/071623 patent/WO2013101810A1/en not_active Ceased
- 2012-12-26 PT PT128086626T patent/PT2797581T/pt unknown
- 2012-12-26 BR BR112014015923-8A patent/BR112014015923B1/pt active IP Right Grant
- 2012-12-26 PL PL12808662T patent/PL2797581T3/pl unknown
- 2012-12-26 DK DK20172615.5T patent/DK3756650T3/da active
- 2012-12-26 AU AU2012362562A patent/AU2012362562B2/en active Active
- 2012-12-26 PL PL20172615.5T patent/PL3756650T3/pl unknown
- 2012-12-26 CN CN201280070694.5A patent/CN104136003A/zh active Pending
- 2012-12-26 CA CA2861594A patent/CA2861594A1/en active Pending
- 2012-12-26 HR HRP20251291TT patent/HRP20251291T1/hr unknown
- 2012-12-26 ES ES12808662T patent/ES2799448T3/es active Active
- 2012-12-26 SG SG11201403564YA patent/SG11201403564YA/en unknown
- 2012-12-26 FI FIEP20172615.5T patent/FI3756650T3/fi active
- 2012-12-26 ES ES20172615T patent/ES3049175T3/es active Active
- 2012-12-26 UA UAA201408510A patent/UA113750C2/uk unknown
- 2012-12-26 MX MX2014007878A patent/MX373934B/es active IP Right Grant
- 2012-12-26 HR HRP20200825TT patent/HRP20200825T1/hr unknown
- 2012-12-26 SM SM20200339T patent/SMT202000339T1/it unknown
- 2012-12-26 LT LTEP20172615.5T patent/LT3756650T/lt unknown
- 2012-12-26 PE PE2014001038A patent/PE20142318A1/es not_active Application Discontinuation
- 2012-12-26 LT LTEP12808662.6T patent/LT2797581T/lt unknown
- 2012-12-26 EP EP20172615.5A patent/EP3756650B1/en active Active
- 2012-12-26 HU HUE12808662A patent/HUE050327T2/hu unknown
- 2012-12-26 EP EP12808662.6A patent/EP2797581B1/en not_active Revoked
- 2012-12-26 SI SI201231796T patent/SI2797581T1/sl unknown
- 2012-12-26 SM SM20250402T patent/SMT202500402T1/it unknown
- 2012-12-26 HU HUE20172615A patent/HUE073430T2/hu unknown
- 2012-12-26 EP EP25181548.6A patent/EP4623993A3/en active Pending
- 2012-12-26 KR KR1020197030218A patent/KR102232154B1/ko active Active
- 2012-12-26 EA EA201491292A patent/EA027801B1/ru not_active IP Right Cessation
- 2012-12-26 RS RS20251057A patent/RS67339B1/sr unknown
-
2014
- 2014-06-22 IL IL233296A patent/IL233296B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04629A patent/ZA201404629B/en unknown
- 2014-06-26 MX MX2020005145A patent/MX2020005145A/es unknown
- 2014-06-26 CL CL2014001726A patent/CL2014001726A1/es unknown
- 2014-06-26 NI NI201400068A patent/NI201400068A/es unknown
- 2014-06-27 PH PH12014501495A patent/PH12014501495B1/en unknown
- 2014-06-27 CR CR20140314A patent/CR20140314A/es unknown
- 2014-07-03 EC ECIEPI20147965A patent/ECSP14007965A/es unknown
- 2014-07-09 CO CO14147911A patent/CO7000777A2/es unknown
-
2020
- 2020-05-14 US US16/874,424 patent/US12576034B2/en active Active
- 2020-06-25 CY CY20201100590T patent/CY1123174T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506356A5 (https=) | ||
| EA029081B9 (ru) | Комбинированный состав двух противовирусных соединений | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| AR092439A1 (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
| SA518391836B1 (ar) | تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه | |
| JP2013014622A5 (https=) | ||
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| NO20091501L (no) | Farmasoytiske sammensetninger | |
| PH12015500313A1 (en) | Orally administered medical composition | |
| FI3756650T3 (fi) | (+)-2-[1-(3-etoksi-4-metoksifenyyli)-2-metaanisulfonyylietyyli]-4-asetyyliaminoisoindoliini-1,3-dionin formulaatioita | |
| MY182884A (en) | Pyrazole-amide compound and medicinal uses therefor | |
| JP2013507408A5 (https=) | ||
| MX377202B (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| WO2012002644A3 (en) | Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability | |
| NZ628993A (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| NZ602450A (en) | Agomelatine hydrochloride hydrate and preparation thereof | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| WO2014197345A3 (en) | Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| WO2010001413A3 (en) | Sustained release pharmaceutical compositions comprising quetiapine | |
| NZ727834A (en) | Fast acting orally disintegrating film | |
| WO2013128419A3 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
| EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
| NZ607225A (en) | Multiple unit tablet composition | |
| JP2013540778A5 (https=) |